SphinCS GmbH

At SphinCS GmbH in Hochheim Am Main, clinical research in this area focuses on rare inherited disorders that begin early in life, especially Pompe disease, Fabry disease, Gaucher disease, and Mucopolysaccharidosis type II. The studies are designed to assess new and supportive treatment options, with attention to safety, symptom control, and long-term benefit.

• Rare pediatric and early-onset lysosomal storage disorders
• Pompe disease, including infantile-onset and late-onset forms
• Fabry disease and Gaucher disease across different patient groups
• Evaluation of therapies intended to improve disease management and daily function

These trials mainly explore whether emerging treatments can better support patients living with inherited metabolic diseases and related complications.

This research site is also active in neurological disease studies, particularly conditions that affect the brain, movement, and coordination. The main focus includes Niemann-Pick disease type C, GM1 gangliosidosis, GM2 gangliosidosis, and neuronopathic forms of Mucopolysaccharidosis type II, with trial goals centered on improving neurological symptoms and measuring treatment effectiveness.

• Niemann-Pick disease type C and related neurodegenerative symptoms
• GM1 and GM2 gangliosidoses
• Neurological involvement in MPS II
• Testing therapies aimed at ataxia, cognition, and overall neurological function

The studies here often look at whether new therapies can slow progression, ease movement problems, and improve quality of life for people with rare brain-related disorders.

Another major research focus at Clinical Science for LSD is metabolic disease, especially disorders where enzyme or substrate imbalance affects multiple organs. Trials are examining Fabry disease, Gaucher disease type 3, and late-onset Pompe disease, with an emphasis on treatment effectiveness, symptom relief, and long-term safety.

• Fabry disease with pain and heart-related concerns
• Gaucher disease type 3 with neurological and cognitive features
• Late-onset Pompe disease and respiratory involvement
• Assessment of therapies used alone or alongside existing standard care

These investigations are aimed at understanding how newer approaches may improve organ function and everyday health in people with rare metabolic conditions.

The site’s trial portfolio also reflects a strong interest in genetic disorders and the biological mechanisms behind them. Research includes inherited conditions such as Fabry disease, Gaucher disease, Pompe disease, and Niemann-Pick disease type C, with studies designed to support better diagnosis, track disease progression, and evaluate new therapeutic strategies.

• Inherited lysosomal storage diseases across pediatric and adult populations
• Studies measuring changes in neurological, cardiac, and respiratory symptoms
• Evaluation of long-term treatment safety and tolerability
• Research into how genetic disease mechanisms may be better addressed by targeted therapies

Overall, the research at SphinCS GmbH brings together multiple rare-disease programs with the shared goal of improving care for patients affected by complex genetic conditions.